These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9570427)

  • 61. Angiotensin-converting enzyme inhibitor improves force and Ca2 +--frequency relationships in myocytes from rats with heart failure.
    Liao X; He J; Ma H; Tao J; Chen W; Leng X; Mai W; Zhen W; Liu J; Wang L
    Acta Cardiol; 2007 Apr; 62(2):157-62. PubMed ID: 17536604
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Different effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on protein metabolism in rats with right ventricular hypertrophy.
    Tanaka K; Honda M; Kuramochi T; Hashimoto M; Masumura S; Mansoor AM; Ishikawa S; Morioka S
    J Hypertens; 1994 Oct; 12(10):1147-54. PubMed ID: 7836730
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity.
    Lindqvist M; Kahan T; Melcher A; Ekholm M; Hjemdahl P
    J Hypertens; 2007 Jan; 25(1):169-75. PubMed ID: 17143189
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of the novel T-selective calcium channel antagonist mibefradil on kidney function in comparison with amlodipine.
    Greven J
    Arzneimittelforschung; 1998 Aug; 48(8):806-10. PubMed ID: 9748707
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mechanism of the antiischemic effect of mibefradil, a selective T calcium channel blocker in dogs: comparison with amlodipine.
    Roux S; Bühler M; Clozel JP
    J Cardiovasc Pharmacol; 1996 Jan; 27(1):132-9. PubMed ID: 8656647
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunomodulating effects of second-generation calcium channel blockers on experimental heart transplantation.
    Lapointe N; Chen H; Qi S; Xu D; Daloze P; Dumont L
    Eur Surg Res; 1999; 31(3):259-66. PubMed ID: 10352354
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cytosolic calcium and lymphoproliferative response during calcium antagonism in men.
    Lijnen P; Fagard R; Petrov V
    Eur J Clin Pharmacol; 1999 Feb; 54(12):911-5. PubMed ID: 10192750
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure.
    Merabet N; Bellien J; Glevarec E; Nicol L; Lucas D; Remy-Jouet I; Bounoure F; Dreano Y; Wecker D; Thuillez C; Mulder P
    J Mol Cell Cardiol; 2012 Mar; 52(3):660-6. PubMed ID: 22155238
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reduction of exercise-induced regional contractile dysfunction in dogs using a novel calcium channel blocker (Ro 40-5967).
    Guth BD
    Cardiovasc Drugs Ther; 1992 Apr; 6(2):167-71. PubMed ID: 1390329
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Blocking of T-type calcium channels: new horizons in the therapeutic potential of calcium antagonists].
    Cerqueira-Gomes M; Maciel MJ; Martins L
    Rev Port Cardiol; 1998 Jan; 17(1):9-15. PubMed ID: 9558949
    [No Abstract]   [Full Text] [Related]  

  • 71. Safety of calcium antagonists in patients with congestive heart failure.
    Katz S
    Clin Ther; 1997; 19 Suppl A():92-113. PubMed ID: 9385507
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial.
    Levine TB; Bernink PJ; Caspi A; Elkayam U; Geltman EM; Greenberg B; McKenna WJ; Ghali JK; Giles TD; Marmor A; Reisin LH; Ammon S; Lindberg E
    Circulation; 2000 Feb; 101(7):758-64. PubMed ID: 10683349
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Beneficial effects of the T- and L-type calcium channel antagonist, mibefradil, against exercise-induced myocardial stunning in dogs.
    Parent de Curzon O; Ghaleh B; Hittinger L; Giudicelli JF; Berdeaux A
    J Cardiovasc Pharmacol; 2000 Feb; 35(2):240-8. PubMed ID: 10672856
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cardiovascular care with the new T-type calcium channel antagonist: possible role of attendant sympathetic nervous system inhibition.
    Bühler FR
    J Hypertens Suppl; 1997 Dec; 15(5):S3-7. PubMed ID: 9481610
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cardioprotective activity of mibefradil.
    van Zwieten PA
    Cardiovasc Res; 1998 Aug; 39(2):276-7. PubMed ID: 9798512
    [No Abstract]   [Full Text] [Related]  

  • 76. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist.
    Triggle DJ
    Am J Cardiol; 1996 Nov; 78(9A):7-12. PubMed ID: 8903279
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of chronic heart failure on the responsiveness to angiotensin I and to angiotensin converting enzyme inhibition with cilazapril in rats.
    Clozel JP
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):167S-174S. PubMed ID: 2527530
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Disparate structural effects on left and right ventricles by angiotensin-converting enzyme inhibitors and calcium antagonists in essential hypertension.
    Aristizabal D; Messerli FH; Frohlich ED
    Am J Cardiol; 1994 Mar; 73(7):483-7. PubMed ID: 8141090
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [The pharmacological and clinical outlook for mibefradil--a new selective T-type calcium channel antagonist].
    Eliseev OM
    Ter Arkh; 1998; 70(8):87-8. PubMed ID: 9841457
    [No Abstract]   [Full Text] [Related]  

  • 80. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction.
    Véniant M; Clozel JP; Hess P; Wolfgang R
    J Cardiovasc Pharmacol; 1991 Feb; 17(2):277-84. PubMed ID: 1709233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.